These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

767 related articles for article (PubMed ID: 15597070)

  • 1. Meningococcal C vaccines: the Canadian experience.
    De Wals P
    Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S280-4. PubMed ID: 15597070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease.
    De Wals P; Nguyen VH; Erickson LJ; Guay M; Drapeau J; St-Laurent J
    Vaccine; 2004 Mar; 22(9-10):1233-40. PubMed ID: 15003652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada.
    Bettinger JA; Scheifele DW; Le Saux N; Halperin SA; Vaudry W; Tsang R;
    Pediatr Infect Dis J; 2009 Mar; 28(3):220-4. PubMed ID: 19209096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain.
    Larrauri A; Cano R; García M; Mateo Sd
    Vaccine; 2005 Jul; 23(32):4097-100. PubMed ID: 15908059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of serogroup C meningococcal polysaccharide vaccine: results from a case-control study in Quebec.
    De Wals P; Deceuninck G; De Serres G; Boivin JF; Duval B; Remis R; Massé R
    Clin Infect Dis; 2005 Apr; 40(8):1116-22. PubMed ID: 15791510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis.
    De Wals P; Coudeville L; Trottier P; Chevat C; Erickson LJ; Nguyen VH
    Vaccine; 2007 Jul; 25(29):5433-40. PubMed ID: 17560695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.
    Pace D
    Expert Rev Vaccines; 2009 May; 8(5):529-42. PubMed ID: 19397410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of serogroup C meningococcal conjugate vaccine: a 7-year follow-up in Quebec, Canada.
    De Wals P; Deceuninck G; Lefebvre B; Boulianne N; De Serres G
    Pediatr Infect Dis J; 2011 Jul; 30(7):566-9. PubMed ID: 21326136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evolution of meningococcal disease in the community of Madrid. Effectiveness of antimeningococcal A+C vaccination].
    Gutiérrez Rodríguez MA; Ramírez Fernández R; García Gutiérrez J; Moreno Civantos A; Hernando García M; Arce Arnáez A; Sendra Gutiérrez JM; Bueno Vallejos R
    Rev Esp Salud Publica; 2000; 74(4):397-403. PubMed ID: 11031849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meningococcal B vaccine: new drug. The only vaccine against some serogroup B meningococci.
    Prescrire Int; 2008 Jun; 17(95):95-7. PubMed ID: 18623907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meningococcal group C disease in Greece during 1993-2006: the impact of an unofficial single-dose vaccination scheme adopted by most paediatricians.
    Kafetzis DA; Stamboulidis KN; Tzanakaki G; Kourea Kremastinou J; Skevaki CL; Konstantopoulos A; Tsolia M
    Clin Microbiol Infect; 2007 May; 13(5):550-2. PubMed ID: 17378929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine.
    De Wals P; Deceuninck G; Boulianne N; De Serres G
    JAMA; 2004 Nov; 292(20):2491-4. PubMed ID: 15562128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
    Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
    Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The first effect of the national vaccination campaign against meningococcal-C disease: a rapid and sharp decrease in the number of patients].
    de Greeff SC; de Melker HE; Spanjaard L; van den Hof S; Dankert J
    Ned Tijdschr Geneeskd; 2003 Jun; 147(23):1132-5. PubMed ID: 12822525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.
    Shepard CW; Ortega-Sanchez IR; Scott RD; Rosenstein NE;
    Pediatrics; 2005 May; 115(5):1220-32. PubMed ID: 15867028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MenACWY-CRM, a novel quadrivalent glycoconjugate vaccine against Neisseria meningitidis for the prevention of meningococcal infection.
    Pace D
    Curr Opin Mol Ther; 2009 Dec; 11(6):692-706. PubMed ID: 20072946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serogroup C meningococcal conjugate vaccines: new preparations. Effective from age two months.
    Prescrire Int; 2003 Apr; 12(64):43-6. PubMed ID: 12675020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making.
    Welte R; van den Dobbelsteen G; Bos JM; de Melker H; van Alphen L; Spanjaard L; Rümke HC; Postma MJ
    Vaccine; 2004 Dec; 23(4):470-9. PubMed ID: 15530695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expanding prevention of invasive meningococcal disease.
    Pelton SI; Gilmet GP
    Expert Rev Vaccines; 2009 Jun; 8(6):717-27. PubMed ID: 19485753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative efficacy of different immunization schedules for the prevention of serogroup C meningococcal disease: a model-based evaluation.
    De Wals P; Trottier P; Pépin J
    Vaccine; 2006 Apr; 24(17):3500-4. PubMed ID: 16517032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.